NCT02764697View on ClinicalTrials.gov

Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 7, 2016

Study Completion Date

December 20, 2016

Conditions
UveitisAnterior UveitisIntermediate UveitisPosterior UveitisScleritisClinically Significant Macular Edema
Interventions
DRUG

H.P. ACTHAR SUBCUTANEOUS GEL INJECTION

Subcutaneous injection twice weekly

Trial Locations (1)

33709

Tampa Bay Uveitis Center, St. Petersburg

Sponsors

Collaborators (1)

Mallinckrodt
All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Tampa Bay Uveitis Center, LLC

OTHER

NCT02764697 - Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients | Biotech Hunter | Biotech Hunter